The Cost-utility analysis (CUA) study of Hematopoietic stem cell transplantation (HSCT) versus blood transfusion and iron chelating therapy (standard treatment) found that related HSCT (sibling donor) is more cost effective than unrelated HSCT in patients ≤ 10 years old in Thai healthcare setting. However, there currently has capacity limit for HSCT provision in Thailand which can not meet all required patients. This situation hinders the implementation of HSCT provision under universal coverage (UC) scheme under National Health Security Office (NHSO) because the low accessibility to this therapy. Therefore, the CUA study is not cover some issues that the policy makers need to know before making the decision. This feasibility study serves the policy makers regarding the wider and comprehensive views besides CUA in order to consider about HSCT provision under UC scheme in Thailand.